Creates provisions relating to insurance coverage of drugs
Summary
HB 2726 adds a new section to Missouri insurance law governing how health carriers and health benefit plans handle prescription drug coverage. For health plans delivered, issued, continued, or renewed in Missouri on or after January 1, 2027, the bill would generally prohibit a carrier from requiring an enrollee to switch from the drug prescribed by the enrollee’s health care provider to a different drug that the carrier considers more appropriate, as a condition of receiving coverage. The only exception is when the enrollee’s provider gives written approval for the change and the change is in the enrollee’s health interest.
The bill preserves existing law on interchangeable biological products and does not interfere with substitution rules under section 338.085. It also expressly excludes prescription drugs subject to step therapy protocols under section 376.2034, meaning those protocols would continue to operate as allowed under current law. In practical terms, the bill would limit insurer-driven drug switching for covered prescriptions while leaving certain substitution and utilization-management tools intact.
Impact
HB 2726 would amend chapter 376, RSMo, by creating section 376.2048 and imposing new restrictions on health carriers and health benefit plans regarding prescription drug coverage. It would affect insurers, health benefit plans, enrollees, and health care providers by requiring provider-written approval before a carrier can force a covered patient to change medications for coverage purposes, subject to the bill’s exceptions. The measure would apply prospectively to plans issued, delivered, continued, or renewed on or after January 1, 2027.
Sentiment
The available context suggests the bill was introduced and referred to the House Emerging Issues Committee, but there are no recorded committee transcripts or votes in the provided materials. As a result, there is no documented floor or committee sentiment to assess beyond the bill’s apparent policy goal of protecting provider-directed drug choices in insurance coverage decisions.
Contention
The main policy tension in HB 2726 is between patient/provider control over medication selection and insurer authority to manage costs and formularies. Supporters would likely view the bill as protecting continuity of care and preventing forced medication changes, while opponents may argue it limits health plan flexibility and could increase costs or reduce utilization-management tools. The bill’s explicit carve-outs for interchangeable biological products and step therapy indicate an effort to narrow, rather than eliminate, insurer drug-management practices.